Parkinsons disease Flashcards
Pathology of PD
neurodegeneration of dopaminergic neurons in pars compacta of the substantia nigra (SNpc) of basal ganglia
Cardinal features of PD (triad)
Bradykinesia
Resting tremor (4-6Hz)
Rigidity hypertonia
Motor features of PD
Bradykinesia Tremor rigidity shuffling gait loss of arm swing stooped postural instability difficulty initiating gait difficulty turning low amplitude finger tapping
Non-motor features of PD
DEPRESSION dementia anosmia constipation REM behavioural disorder hypomimia micrographia hypersalivation hallucinations GI dysfunction
Causes of Parkinsonism
idiopathic PD
drugs: metaclopramide, haloperidol, lithium, B blockers
environmental/chemical exposure
MS, Wilson’s, post encephalitis
management of PD
Levodopa +-carbidopa
dopamine agonists
PT, OT, S+LT
describe dementia in Parkinsons
dementia:
- less than 1 year = DLB
- more than 1 year = PDD
Parkinsonism has a/symmetrical tremor
Parkinsons disease has a/symmetrical tremor
parkinsonism is symmetrical
parkinsons disease is asymmetrical
on macroscopic pathological specimens what can be noted
loss of normal black pigment in the substantia nigra (and locus coeruleus)
what is a neurohistological hallmark of PD
Lewy bodies containing a-synuclein
however, not specific to PD
what are the subtypes of motor features in PD
tremor dominant PD
non-tremor dominant PD
mixed
describe tremor dominant PD and what is the prognosis
relative absenceof other motor symptoms
slower rate of progression
describe non-tremor dominant PD
akinetic rigid syndrome and postural instability gait syndrome
imaging is part of the routine diagnostic work up in PD, true or false
false, PD is largely a clinical diagnosis
it is only used when there is uncertainty
which imaging types are structural
MRI
CT
which imaging types are functional
PET
SPECT
DaTSCAN
Risk factors for developing PD
advancing age
positive family history + genetics
male gender
environmental factors: pesticides, rural living, B blocker, prior head injury
monogenetic forms of PD
LRRK2 - AD
PARKIN - AR
what is the function of symptomatic treatments
increase dopamine concentrations or stimulate dopamine receptors
when should treatment be initiated
when symptoms cause disability or discomfort
with the aim of improving quality of life